215 related articles for article (PubMed ID: 16305662)
1. Regulatory T cells in ovarian cancer: biology and therapeutic potential.
Barnett B; Kryczek I; Cheng P; Zou W; Curiel TJ
Am J Reprod Immunol; 2005 Dec; 54(6):369-77. PubMed ID: 16305662
[TBL] [Abstract][Full Text] [Related]
2. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape mechanisms in prostate cancer.
Miller AM; Pisa P
Cancer Immunol Immunother; 2007 Jan; 56(1):81-7. PubMed ID: 16362411
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
5. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
6. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
Tseng-Rogenski SS; Arredouani MS; Neeley YC; Lu B; Chinnaiyan AM; Sanda MG
Cancer Immunol Immunother; 2008 Sep; 57(9):1357-65. PubMed ID: 18265979
[TBL] [Abstract][Full Text] [Related]
7. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
Kryczek I; Wei S; Zhu G; Myers L; Mottram P; Cheng P; Chen L; Coukos G; Zou W
Cancer Res; 2007 Sep; 67(18):8900-5. PubMed ID: 17875732
[TBL] [Abstract][Full Text] [Related]
8. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
Jaeckel E; Mpofu N; Saal N; Manns MP
Horm Metab Res; 2008 Feb; 40(2):126-36. PubMed ID: 18283631
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.
Wei S; Kryczek I; Edwards RP; Zou L; Szeliga W; Banerjee M; Cost M; Cheng P; Chang A; Redman B; Herberman RB; Zou W
Cancer Res; 2007 Aug; 67(15):7487-94. PubMed ID: 17671219
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors on regulatory T cells: expanding immune regulation.
Sutmuller RP; Morgan ME; Netea MG; Grauer O; Adema GJ
Trends Immunol; 2006 Aug; 27(8):387-93. PubMed ID: 16814607
[TBL] [Abstract][Full Text] [Related]
12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells and asthma.
Robinson DS
Clin Exp Allergy; 2009 Sep; 39(9):1314-23. PubMed ID: 19538496
[TBL] [Abstract][Full Text] [Related]
14. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
Masteller EL; Tang Q; Bluestone JA
Semin Immunol; 2006 Apr; 18(2):103-10. PubMed ID: 16458533
[TBL] [Abstract][Full Text] [Related]
17. Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
Horn T; Grab J; Schusdziarra J; Schmid S; Maurer T; Nawroth R; Wolf P; Pritsch M; Gschwend JE; Kübler HR; Beckhove P
Int J Cancer; 2013 Nov; 133(9):2145-56. PubMed ID: 23625723
[TBL] [Abstract][Full Text] [Related]
18. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
19. Natural T cell immunity against cancer.
Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U
Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498
[TBL] [Abstract][Full Text] [Related]
20. Taming cancer by inducing immunity via dendritic cells.
Palucka AK; Ueno H; Fay JW; Banchereau J
Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
